Last call for nominations on notable women in biopharma

Over the last few weeks we've gathered dozens of excellent nominations for our annual issue on the most notable women in biopharma. And I wanted to offer up one last chance for readers to submit a name before we close the books and make the final selection.

Like most of our annual specials, this report is based on the life sciences team's work over the past year. As women have risen steadily in the ranks on both the science side and the business end of drug development, they are increasingly in line for top jobs in the industry. And they are making headlines.

They are also blazing a path that will be followed by a new generation of biopharma leaders. 

This is our third special report on women in the industry. With your help, we hope to make it the best one to date. So if you know someone who should be highlighted--and hasn't been on the list before--get your nomination in by COB next Friday. 

Here's the survey >>

As a handy guide to the qualities we're looking for, here's a look at past winners. -- John Carroll, Editor-in-Chief. Follow me on Twitter and LinkedIn.

  • FierceBiotech's 2010 Women in Biotech
  • FierceBiotech's 2011 Women in Biotech

Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

Durect’s share price fell 12% after half of the panel of painkiller experts recommended against approving Posimir.

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite.